Our graduates successfully completed the first Winter mRNA Masterclass, a week-long intensive program that trains students in the science, computational design, and laboratory production of mRNAs and LNPs.

We published our step-by-step protocol for mRNA-LNP production, describing the design, manufacture, and quality control of mRNA medicines using standard equipment in a research laboratory.

In partnership with Vaxxas, BASE scientists were awarded the BARDA Patch Forward Prize to develop mRNA vaccines delivered using high-density microarray patches (HD-MAPs).

BASE scientists released mRNArchitect, a software platform for designing mRNA medicines. The software enables users to optimise mRNA sequences for improved translation efficiency, stability, and immunogenicity, and has been experimentally validated across a wide range of applications.

The targeted delivery of mRNA therapeutics remains a major challenge in treating disease. BASE scientists have published a method in Molecular Therapy – Nucleic Acids that directs mRNA–LNPs to specific cells and tissues using bispecific antibodies that bind mRNA–LNPs to cell-surface receptors.

BASE has partnered with Oxford Nanopore Technologies to develop nanopore sequencing methods for analysing mRNA during manufacture. These technologies enable measurement of mRNA sequence, integrity, and purity to support improved quality control.

BASE scientists have been awarded funding from the Medical Research Future Fund (MRFF) to provide cancer researchers with access to personalised mRNA vaccine technologies. This funding will enable researchers to design mRNA cancer vaccines tailored to individual patients.

In partnership with Oxford Nanopore Technologies, BASE has been awarded funding from the Australian Research Council (ARC) to routinely integrate nanopore sequencing into mRNA manufacturing processes.

BASE has received funding from the Medical Research Future Fund (MRFF) and Sanofi to establish a national mRNA–LNP production facility supporting translational research by Australian scientists.

BASE scientists have developed a method, published in Nature Communications, using nanopore sequencing to analyse the quality of mRNA vaccines. This approach enables real-time analysis of mRNA molecules at single-molecule resolution.